Welcome to our dedicated page for Catalyst Pharmaceuticals news (Ticker: CPRX), a resource for investors and traders seeking the latest updates and insights on Catalyst Pharmaceuticals stock.
Catalyst Pharmaceuticals reports developments as a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing medicines for rare and difficult-to-treat diseases. Its recurring updates center on the commercial performance of FIRDAPSE® (amifampridine), AGAMREE® (vamorolone), and FYCOMPA® (perampanel), along with financial results, revenue guidance, conference presentations, and business updates.
Company news also covers product-specific medical and legal developments, including vamorolone research in Duchenne muscular dystrophy and patent litigation settlements involving FIRDAPSE. Additional announcements address patient advocacy initiatives, support services, and strategic portfolio activity tied to Catalyst’s U.S.-based rare-disease commercial model.
Catalyst Pharmaceuticals (Nasdaq: CPRX) announced Health Canada’s approval of Firdapse® (amifampridine) for treating Lambert-Eaton myasthenic syndrome (LEMS), a rare neurodegenerative condition. The approval was granted under Priority Review based on data from two multinational clinical trials. Firdapse® was previously approved in the U.S. and Europe. Catalyst is exploring partnerships for distribution in Canada and aims to expand Firdapse® indications. LEMS is often linked to autoimmune disorders and can be life-threatening.
Catalyst Pharmaceuticals (Nasdaq: CPRX) has transitioned its 2020 Annual Meeting of Stockholders to a virtual-only format due to the COVID-19 pandemic. The meeting is scheduled for August 20, 2020, at 9:00 AM ET. Stockholders can participate in voting and submitting questions via an online platform. Only those registered by June 22, 2020, can attend. The company has provided detailed instructions for both registered and street name stockholders to register for the meeting. Additionally, the Proxy Statement and related information are available on their website.
Catalyst Pharmaceuticals (Nasdaq: CPRX) will release its Q2 2020 financial results after market close on August 10, 2020. An investment-community conference call is scheduled for August 11, 2020, at 8:30 a.m. ET to discuss the results and provide a corporate update. Investors can participate by calling (877) 407-8912 for domestic and (201) 689-8059 for international callers, or stream via the company's website. A webcast replay will be available for 30 days post-call.
Catalyst Pharmaceuticals (CPRX) announced a disappointing recommendation from a Magistrate Judge regarding its lawsuit against the FDA, advising to deny Catalyst's motion for summary judgment. The recommendation, which Catalyst believes is legally flawed, could jeopardize the exclusivity benefits of the Orphan Drug Act. Chairman Patrick J. McEnany stated that if upheld, the decision could discourage investment in orphan drug development. Despite this setback, Catalyst remains committed to protecting its drug Firdapse® from competition.
Catalyst Pharmaceuticals (Nasdaq: CPRX) announced several leadership promotions, including Jeffrey Del Carmen to Chief Commercial Officer. Del Carmen, who previously served as Senior Vice President of Sales and Marketing, will lead efforts to expand access to the company's Firdapse product for Lambert-Eaton myasthenic syndrome (LEMS) and prepare for a potential launch for anti-MuSK antibody positive myasthenia gravis. The company also promoted Pete Curry to Vice President of Sales and Maria Pandolfo to Vice President of Patient Services.
Catalyst Pharmaceuticals, focused on rare neuromuscular diseases, announced its presentation at the Jefferies Virtual Healthcare Conference on June 2-4, 2020. CEO Patrick J. McEnany and CSO Steven Miller will host one-on-one investor meetings, with their presentation on June 4 at 8:30 a.m. E.T. The event will be accessible via the company's investor webpage. Catalyst's Firdapse® (amifampridine) is FDA-approved for Lambert-Eaton myasthenic syndrome and is under evaluation for other conditions. The press release emphasizes Catalyst's commitment to innovative therapies.
Catalyst Pharmaceuticals (Nasdaq: CPRX) reported Q1 2020 net revenues of $29.1 million, a 134% increase from the previous year. The company achieved a GAAP net income of $10.4 million or $0.10 per share, compared to a loss of $645,000 in Q1 2019. Catalyst withdrew its 2020 revenue guidance due to COVID-19 uncertainties while highlighting minimal impact on Q1 revenues. The firm ended the quarter with $101.8 million in cash and no debt and expanded its sales force to enhance the Firdapse franchise. Upcoming milestones include Phase 3 trial results for MuSK-MG expected in Q3 2020.
Summary not available.